Lingohr Asset Management GmbH Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Lingohr Asset Management GmbH purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 8,647 shares of the biopharmaceutical company's stock, valued at approximately $796,000. Gilead Sciences accounts for 1.6% of Lingohr Asset Management GmbH's holdings, making the stock its 20th largest position.

Other institutional investors have also modified their holdings of the company. iA Global Asset Management Inc. boosted its stake in Gilead Sciences by 14.2% in the fourth quarter. iA Global Asset Management Inc. now owns 199,882 shares of the biopharmaceutical company's stock valued at $18,463,000 after acquiring an additional 24,815 shares during the period. Teacher Retirement System of Texas boosted its position in Gilead Sciences by 32.1% during the 4th quarter. Teacher Retirement System of Texas now owns 442,579 shares of the biopharmaceutical company's stock valued at $40,881,000 after purchasing an additional 107,566 shares during the period. Grey Fox Wealth Advisors LLC bought a new position in Gilead Sciences during the 4th quarter worth $211,000. Generali Investments Management Co LLC acquired a new stake in Gilead Sciences in the fourth quarter worth $1,095,000. Finally, Harvest Fund Management Co. Ltd lifted its stake in Gilead Sciences by 41.0% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 80,889 shares of the biopharmaceutical company's stock valued at $7,375,000 after buying an additional 23,512 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Morgan Stanley increased their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a report on Tuesday, March 11th. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. BMO Capital Markets increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, Piper Sandler raised their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $104.52.

Remove Ads

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 302,785 shares of company stock valued at $30,503,250. Insiders own 0.16% of the company's stock.

Gilead Sciences Stock Down 0.3 %

NASDAQ:GILD traded down $0.34 during trading hours on Monday, hitting $106.74. 8,562,938 shares of the stock traded hands, compared to its average volume of 6,800,396. The firm has a market cap of $132.93 billion, a price-to-earnings ratio of 288.49, a PEG ratio of 0.71 and a beta of 0.21. The firm has a 50 day moving average price of $104.01 and a 200 day moving average price of $94.15. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.96%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is currently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.